- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04925921
AVAVA SR-1 Wrinkles and BPL Study
December 11, 2023 updated by: AVAVA, Inc.
This study is being conducted to evaluate the safety and efficacy of a laser called the SR-1 Skin Treatment System, or SR-1 Laser, for the treatment of wrinkles and pigmented spots.
Participants will be treated with the SR-1 Laser 3 or 4 times with each treatment spaced 4-6 weeks apart.
The improvement in wrinkles and pigmented spots will be evaluated 1 and 3 months after the final treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Waltham, Massachusetts, United States, 02451
- AVAVA, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
22 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Wrinkles on both sides of the face (e.g., peri-oral, peri-orbital, and cheek) scored 4-9 on the Fitzpatrick Wrinkle and Elastosis Scale
- Willingness to have both sides of the face exposed to the SR-1 Laser.
- Willingness to have digital photographs taken of their face and agreement with use of photographs, with their identity protected, for presentation, educational, or marketing purposes.
Willingness to comply with the following during the study, including the follow-up period:
- maintain consistent skin care regimen on treated areas
- cover treated areas or have very limited sun exposure and use a provided sunscreen as directed by the Investigator
- refrain from using systemic corticosteroids
- refrain from using systemic or topical skin-lightening medications or retinoids
- refrain from any other procedures in the treatment areas
- Willingness and ability to comply with study instructions and return for required visits.
Exclusion Criteria:
Skin pathology or condition, or medication use that could interfere with evaluation of the study procedure, e.g.,
- Isotretinoin use within previous 6 months
- Surgical treatment in the target areas within previous 6 months
- Active vitiligo, psoriasis, or eczema, or history of these in the treatment area
- Injection of botulinum toxin in the treatment areas within the previous 3 months.
- Facial cosmetic procedures in the target areas within previous 6 months (e.g., laser or other energy-based device treatment, microdermabrasion, microneedling, chemical peel, injection of dermal filler).
- Current smoker or history of smoking greater than 0.5 pack/day in past 5 years.
- Excessive sun exposure in the previous month, or unable or unlikely to refrain from tanning or excessive sun exposure during the study.
- Artificial tanning (e.g., tanning bed or tanning lotion/spray) in the target areas within previous 1 month or intention to use artificial tanning during the study.
- Active localized or systemic infection, or an open wound in area being treated.
- History of abnormal wound healing or abnormal scarring (e.g., hypertrophic or keloid).
- History of connective tissue disease, such as lupus or scleroderma.
- History of seizure disorders due to light.
- Any use of medication that is known to increase sensitivity to light according to Investigator's discretion (e.g., topicals sensitive to light may be used in other areas off-face).
- History of gold therapy.
- History of disease stimulated by heat, such as recurrent herpes simplex or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.
- History of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer. Current cancerous lesion in the treatment area.
- Pregnancy or lactation, or intent to become pregnant within the study period.
- Significant uncontrolled concurrent illness, such as diabetes mellitus, hypertension, or cardiovascular disease.
- History of immunosuppression/immune deficiency disorder or currently using immunosuppressive medications.
- Planned weight loss of greater than five pounds.
- Facial hair in the treatment areas which would prevent evaluation of the outcome measures.
- Current enrollment in a clinical study of any other investigational drug or device, or has received an investigational drug or been treated with an investigational device within 6 months prior to entering this study, unless the other clinical study only involves noninvasive imaging.
- Any other physical or mental condition, or laboratory value, that would, in the professional opinion of the Investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Treatment with the SR-1 Laser
|
3-4 treatments at 4-6 week intervals
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in facial wrinkles
Time Frame: 3 months after the final treatment
|
A 1 point or greater reduction in facial wrinkle severity using the Fitzpatrick Wrinkle and Elastosis Scale (FWS), as assessed, and agreed upon by at least two of three blinded independent reviewers in at least 70% of subjects as determined with a side-by-side evaluation of baseline and post-treatment photographs.
The FWS scores range from 1 to 9 with lower numbers representing less severe wrinkles.
|
3 months after the final treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction of pigmentation in benign pigmented lesions (BPL)
Time Frame: 3 months after the final treatment
|
If clinically identifiable BPL were present at baseline, a greater than 25% reduction in pigmentation of BPL (including, but not limited to, lentigos, solar lentigos, ephelides, and melasma) as assessed, and agreed upon, by at least two of three blinded independent reviewers in at least 50% of subjects as determined with a side-by-side evaluation of baseline and post-treatment photographs.
|
3 months after the final treatment
|
Subject satisfaction with the improvement in wrinkles
Time Frame: 1 and 3 months after the final treatment
|
The percent of subjects satisfied with the improvement in fine lines and wrinkles in the treated areas will be assessed using a Likert scale with responses ranging from "very dissatisfied" to "very satisfied".
|
1 and 3 months after the final treatment
|
Subject satisfaction with the improvement in BPL
Time Frame: 1 and 3 months after the final treatment
|
The percent of subjects satisfied with the improvement in BPL pigmentation will be assessed among subjects with clinically identifiable BPL present at baseline using a Likert scale with responses ranging from "very dissatisfied" to "very satisfied".
|
1 and 3 months after the final treatment
|
Tolerance of procedure
Time Frame: during treatment
|
Subject tolerance of the procedure based on pain scores during treatment per the 1-10 Visual Analog Scale.
|
during treatment
|
Adverse Events
Time Frame: 3 months after the final treatment
|
The incidence and severity of adverse events
|
3 months after the final treatment
|
Overall improvement
Time Frame: 1 and 3 months after the final treatment
|
Rate of overall improvement in facial wrinkles and BPL in the treated area(s) as assessed by the investigator using the Global Aesthetic Improvement Scale (GAIS).
Wrinkles and BPL will be considered together and one overall score will be created.
Scores on the GAIS range from 0 to 4 which correspond to "worsening of conditions", "no improvement in conditions", "mild improvement in conditions", "moderate improvement in conditions", and "significant improvement in conditions".
|
1 and 3 months after the final treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Fitzpatrick RE, Goldman MP, Satur NM, Tope WD. Pulsed carbon dioxide laser resurfacing of photo-aged facial skin. Arch Dermatol. 1996 Apr;132(4):395-402.
- Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988 Jun;124(6):869-71. doi: 10.1001/archderm.124.6.869. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 10, 2021
Primary Completion (Actual)
December 22, 2021
Study Completion (Actual)
July 25, 2022
Study Registration Dates
First Submitted
June 2, 2021
First Submitted That Met QC Criteria
June 8, 2021
First Posted (Actual)
June 14, 2021
Study Record Updates
Last Update Posted (Estimated)
December 12, 2023
Last Update Submitted That Met QC Criteria
December 11, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- AV-21-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wrinkle
-
Physicians Laser and Dermatology InstituteRecruiting
-
Shanghai Dermatology HospitalRecruiting
-
Integrative Skin Science and ResearchActeraActive, not recruiting
-
Cynosure, Inc.Terminated
-
Saie BeautyCompleted
-
HaEmek Medical Center, IsraelUnknown
-
Mayo ClinicRecruiting
-
Candela CorporationActive, not recruitingWrinkleUnited States, Israel
-
Novoxel Ltd.TerminatedWrinkleUnited States, Israel
-
Goldman, Butterwick, Fitzpatrick and GroffUnknown
Clinical Trials on SR-1 Laser
-
AbbVieCompletedOcular Hypertension | Glaucoma, Open-AngleUnited States, Australia, Canada, Denmark, France, Germany, Israel, New Zealand, Philippines, Russian Federation, United Kingdom, Poland
-
AllerganCompletedGlaucoma | Open-Angle Ocular HypertensionSpain, United States, Singapore, Australia, Denmark, France, Poland, Russian Federation, Thailand
-
Henry Ford Health SystemAmerican Academy of Cosmetic SurgeryCompletedPost Surgical ScarsUnited States
-
Manchester University NHS Foundation TrustTopcon Corporation; Optos, PLCWithdrawnDiabetic Macular OedemaUnited Kingdom
-
Jaeb Center for Health ResearchNational Eye Institute (NEI)CompletedDiabetic Macular Edema
-
University of Alabama at BirminghamNot yet recruiting
-
G&E Herbal Biotechnology Co., LTDCompletedActinic Keratosis | Bowen's DiseaseTaiwan
-
Cynosure, Inc.Completed
-
Otsuka Pharmaceutical Development & Commercialization...Completed
-
NYU Langone HealthTerminatedIschemic Heart DiseaseUnited States